PTC 테라퓨틱스(PTCT)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $65.37 (-3.87%), 시가총액 $6.03B, 52주 범위 $43.30 ~ $86.25.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
PTC 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
PTC 테라퓨틱스의 현재 주가는 $65.37 (-3.87%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
PTC 테라퓨틱스의 시가총액은 약 $6.03B입니다.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States…